PTGS2 and neoplasm: The rationale for defining COX-2 as an emerging therapeutic and chemoprevention target for various cancers [52–54] includes experimental evidence for a role in carcinogenesis or angiogenesis using animal or cell models, together with evidence on the overexpression of COX-2 in tumor malignant cells [27,28,54].